Literature DB >> 25757679

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.

Camille C Gunderson1, Kathleen N Moore.   

Abstract

Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. It has been tested in Phase I and II trials and has single-agent activity in both germline BRCA mutated and sporadic ovarian cancer. Phase III trials assessing the efficacy of olaparib in the maintenance setting following first line and platinum-sensitive recurrence are underway for patients with a germline BRCA mutation, given the inherent molecular compatibility with the drug's mechanism of action.

Entities:  

Keywords:  BRCA mutation; PARP inhibitor; homologous recombination pathway; olaparib; ovarian cancer

Mesh：

Substances：

Year:  2015        PMID： 25757679     DOI： 10.2217/fon.14.313

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  28 in total

Review 1.  Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Emmanouil Kalampokas; Theodoros Kalampokas; Eleftherios Spartalis; Afrodite Daskalopoulou; Serena Valsami; Michael Kontos; Afroditi Nonni; Konstantinos Kontzoglou; Despina Perrea; Nikolaos Nikiteas; Dimitrios Dimitroulis
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

2.  Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.

Authors:  Wael Jdey; Sylvain Thierry; Christophe Russo; Flavien Devun; Muthana Al Abo; Patricia Noguiez-Hellin; Jian-Sheng Sun; Emmanuel Barillot; Andrei Zinovyev; Inna Kuperstein; Yves Pommier; Marie Dutreix
Journal:  Clin Cancer Res       Date:  2016-08-24       Impact factor: 12.531

3.  Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.

Authors:  Christian Rolfo; Judith de Vos-Geelen; Nicolas Isambert; L Rhoda Molife; Jan H M Schellens; Jacques De Grève; Luc Dirix; Peter Grundtvig-Sørensen; Guy Jerusalem; Karin Leunen; Morten Mau-Sørensen; Ruth Plummer; Maria Learoyd; Wendy Bannister; Anitra Fielding; Alain Ravaud
Journal:  Clin Pharmacokinet       Date:  2019-09       Impact factor: 6.447

Review 4.  Programmed cell death in aortic aneurysm and dissection: A potential therapeutic target.

Authors:  Abhijit Chakraborty; Yang Li; Chen Zhang; Yanming Li; Scott A LeMaire; Ying H Shen
Journal:  J Mol Cell Cardiol       Date:  2021-09-28       Impact factor: 5.000

5.  Human PARP1 Facilitates Transcription through a Nucleosome and Histone Displacement by Pol II In Vitro.

Authors:  Elena Y Kotova; Fu-Kai Hsieh; Han-Wen Chang; Natalia V Maluchenko; Marie-France Langelier; John M Pascal; Donal S Luse; Alexey V Feofanov; Vasily M Studitsky
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

6.  Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.

Authors:  Moureq Alotaibi; Khushboo Sharma; Tareq Saleh; Lawrence F Povirk; Eric A Hendrickson; David A Gewirtz
Journal:  Radiat Res       Date:  2016-03-02       Impact factor: 2.841

Review 7.  Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Authors:  Marta Szajnik; Małgorzata Czystowska-Kuźmicz; Esther Elishaev; Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2016-06-23       Impact factor: 5.225

8.  Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.

Authors:  Christian Rolfo; Nicolas Isambert; Antoine Italiano; L Rhoda Molife; Jan H M Schellens; Jean-Yves Blay; Thomas Decaens; Rebecca Kristeleit; Olivier Rosmorduc; Regina Demlova; Myung-Ah Lee; Alain Ravaud; Katerina Kopeckova; Maria Learoyd; Wendy Bannister; Gershon Locker; Judith de Vos-Geelen
Journal:  Br J Clin Pharmacol       Date:  2020-04-05       Impact factor: 4.335

9.  Novel Pyran-Linked Phthalazinone-Pyrazole Hybrids: Synthesis, Cytotoxicity Evaluation, Molecular Modeling, and Descriptor Studies.

Authors:  M Shaheer Malik; Basim H Asghar; Riyaz Syed; Reem I Alsantali; Moataz Morad; Hatem M Altass; Ziad Moussa; Ismail I Althagafi; Rabab S Jassas; Saleh A Ahmed
Journal:  Front Chem       Date:  2021-05-24       Impact factor: 5.221

Review 10.  DNA Damage Response in the Adaptive Arm of the Immune System: Implications for Autoimmunity.

Authors:  Theodora Manolakou; Panayotis Verginis; Dimitrios T Boumpas
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.